Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:18 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
NCT02812056 · M.D. Anderson Cancer Center · PHASE1 · withdrawn · last registry update 2017-03-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AURKA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00853307)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (NCT00807495)
- 2018-03-27Results posted on the registry: Millennium Pharmaceuticals, Inc., Alisertib (MLN8237) + Rituximab (NCT01397825)
- 2017-12-06Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Alisertib + Abiraterone acetate (NCT01848067)
- 2017-11-29Results posted on the registry: Weill Medical College of Cornell University, MLN8237 (NCT01799278)
- 2017-11-20Also stopped (terminated): UNC Lineberger Comprehensive Cancer Center, Alisertib (NCT02700022)
- 2017-11-07Results posted on the registry: University Health Network, Toronto, ENMD-2076 (NCT01719744)
- 2017-06-05Results posted on the registry: Children's Oncology Group, Alisertib (NCT01154816)
- 2016-12-28Results posted on the registry: National Cancer Institute (NCI), Alisertib (NCT01653028)
- 2016-08-15Results posted on the registry: Millennium Pharmaceuticals, Inc., MLN8237 (Alisertib) (NCT01045421)
- 2016-05-30Results posted on the registry: Vanderbilt-Ingram Cancer Center, TdT-mediated dUTP nick end labeling assay (NCT01316692)
- 2016-05-30Also stopped (terminated): Vanderbilt-Ingram Cancer Center, TdT-mediated dUTP nick end labeling assay (NCT01316692)
- 2016-05-25Results posted on the registry: Mayo Clinic, Aurora A kinase inhibitor MLN8237 + bortezomib (NCT01034553)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision